

ALLIGATOR BIOSCIENCE CAPITAL MARKETS DAY

STOCKHOLM ON MAY 29, 2018

Agenda.

WELCOME Charlotte Stjerngren, Moderator

INTRODUCTION Per Norlén, CEO

THE ALLIGATOR STORY Carl Borrebaeck, Co-founder

NAVIGATING COMPLEXITY Peter Ellmark, VP Discovery

ADC-1013 and ATOR-1015 Charlotte Russell, CMO

Break 15.30

ATOR-1017 and ALG.APV-527 Christina Furebring, SVP Research

MARKET OVERVIEW Anu Balendran, VP Business Development

FINANCE Per-Olof Schrewelius, CFO

CONCLUSION Per Norlén, CEO

Q&A Charlotte Stjerngren, Moderator

Networking 17.00

About Alligator Bioscience

Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator's growing pipeline includes four lead clinical and pre-clinical drug candidates (ADC-1013, ATOR-1015, ATOR-1017 and ALG.APV-527). ADC-1013 (JNJ-7107) is licensed to Janssen Biotech, Inc., part of J&J, for global development and commercialization. Alligator's shares are listed on Nasdaq Stockholm (ATORX). The Company is headquartered in Lund, Sweden, and has approximately 50 employees. For more information, please visit www.alligatorbioscience.com.